Menveo Injection
Menveo Injection is a conjugate vaccine used to prevent meningococcal infections caused by Neisseria meningitidis serogroups A, C, W-135, and Y. It helps the body develop immunity against life-threatening illnesses such as meningitis and septicaemia. It is suitable for infants from 6 weeks of age, as well as children, adolescents, and adults.
Contact us for sales assistance from our Biomedical Engineer.
Features:
-
Conjugate Vaccine: Includes polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y conjugated to CRM197 protein for enhanced immune response.
-
Broad-Spectrum Protection: Covers four major meningococcal strains.
-
Pediatric to Adult Use: Approved for use from 6 weeks of age and up.
-
Long-Term Immunity: Stimulates robust, lasting antibody production.
-
Safe Administration: Given by healthcare professionals via intramuscular injection.
| Technical Specification |
|
|---|
1 Vial: 0.5 ml Injection
-
Comprehensive Protection: Shields against four invasive strains of Neisseria meningitidis.
-
Early Immunization: Can be used in infants as young as 6 weeks old.
-
Proven Safety Profile: Well-tolerated with minimal, short-term side effects.
-
Prevention of Life-Threatening Diseases: Reduces risk of meningitis and septicemia.
-
Immune Memory: Promotes long-term immune memory via conjugate technology.
